Scarica l'app Stockscreener
1.89
33.10%
0.47
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Kirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors - TradingView
Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL - insights.citeline.com
Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com India
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aldeyra vows to go ahead after fresh reproxalap setback - The Pharma Letter
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - markets.businessinsider.com
Jefferies cuts Aldeyra stock target to $6, maintains Buy rating - Investing.com India
Jefferies cuts Aldeyra stock target to $6, maintains Buy rating By Investing.com - Investing.com UK
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA - BioSpace
H.C. Wainwright maintains Buy on Aldeyra stock, target at $10 - Investing.com India
Aldeyra Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Aldeyra Therapeutics, Inc. (ADLX) - ACCESS Newswire
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health - TipRanks
ADLX STOCK ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - markets.businessinsider.com
Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX - TradingView
Reproxalap rapped again in DED; second Aldeyra CRL - BioWorld MedTech
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - MSN
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
Top Midday Decliners - MarketScreener
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Sta - Asianet Newsable
US FDA declines to approve Aldeyra's eye disease drug - Reuters
Crude Oil Dips 7%; ISM Services PMI Falls In March - Benzinga
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire
Small cap wrap: Excellon Resources, Trust Stamp, Aldeyra Therapeutics... - Proactive Investors
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud ... - Bluefield Daily Telegraph
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm - GlobeNewswire
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy - Proactive financial news
U.S. FDA declines to approve Aldeyra’s eye disease drug - PharmaLive
US FDA declines to approve Aldeyra’s eye disease drug - The Mighty 790 KFGO
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic - MSN
Aldeyra tumbles as FDA snubs dry eye disease therapy - MSN
FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap - Optometry Times
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall - Benzinga
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns - Benzinga
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease TreatmentShares Slump Pre-Bell - MarketScreener
Aldeyra Therapeutics stock tumbles after FDA setback By Investing.com - Investing.com South Africa
Aldeyra Therapeutics stock tumbles after FDA setback - Investing.com India
Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection - GuruFocus
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery - Fierce Biotech
Aldeyra stock tumbles as FDA snubs lead drug (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission - Investing.com
Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease - MarketScreener
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan - Stock Titan
Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register
Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register
FDA Action Alert: Amgen, Aldeyra and Argenx - BioSpace
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trend Tracker for (ALDX) - news.stocktradersdaily.com
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average – Here’s Why - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX - Business Wire
BTIG maintains Aldeyra stock Buy rating, $11 target By Investing.com - Investing.com Canada
Aldeyra Therapeutics Beats Investor Suit Over Eye Drug Misses - Bloomberg Law News
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):